Antiemetics

A 52-year-old woman undergoing chemotherapy with cisplatin develops severe nausea and vomiting. Among the following antiemetic agents, which is the most commonly used first-line agent for chemotherapy-induced nausea and vomiting (CINV) in current clinical practice?

A 52-year-old woman receiving cisplatin chemotherapy develops severe nausea and vomiting despite ondansetron monotherapy. Which feature best distinguishes aprepitant from ondansetron and justifies its addition to the regimen?

Which of the following antiemetics acts as a selective antagonist of dopamine D2 receptors in the chemoreceptor trigger zone?

A 32-year-old woman undergoing chemotherapy for breast cancer (doxorubicin + cyclophosphamide) presents to the oncology clinic for her second cycle. During the first cycle, she experienced severe nausea and vomiting despite receiving ondansetron 8 mg IV before treatment. Her oncologist decides to add a second antiemetic agent to improve control. Which of the following is the most appropriate addition based on mechanism of action?

A 58-year-old man with advanced gastric cancer is admitted for palliative care. He is on morphine 20 mg 6-hourly for pain and complains of persistent nausea and vomiting. His renal function is normal (eGFR 78 mL/min/1.73 m²), and he is not on any other medications. The palliative care team wants to add an antiemetic that is particularly effective for opioid-induced nausea and vomiting (OINV). Which agent is most appropriate?